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Abstract
Background: Prescription of non-steroidal anti-inflammatory drugs (NSAIDs) should be based on the assessment of
both gastrointestinal (GI) and cardiovascular (CV) risk for the individual patient. We aimed to assess the GI/CV risk
profile and the pharmacological management of patients with osteoarthritis (OA) in clinical practice.
Methods: We conducted a cross-sectional, multicentre, observational study of consecutive OA patients that visited
1,760 doctors throughout the Spanish National Health System (NHS) in a single day. The presence of GI risk factors,
CV histories, hypertension and current pharmacological treatments was recorded.
Results: Of the 60,868 patients, 17,105 had a diagnosis of OA and were evaluable. The majority (93.4%) had more
than one GI risk factor and 60.3% were defined to be at high-GI risk. Thirty-two percent had a history of CV events,
57.6% were treated with anti-hypertensive therapy and 22.6% had uncontrolled hypertension. One-fifth of patients
were treated with non-NSAID therapies, whereas the remaining patients received NSAIDs. Non-selective NSAIDs
(nsNSAID) plus proton pump inhibitor (PPI) or cyclooxigenase-2 (COX-2)-selective NSAIDs alone were more
frequently prescribed in patients at increased GI risk. Patients with a positive CV history received nsNSAIDs or COX-
2-selective NSAIDs in 41.3% and 31.7% of cases, respectively. When both the GI and CV histories were combined,
51% of the overall population was being prescribed drugs that were either not recommended or contraindicated.
Conclusions: Over 90% of patients with OA are at increased GI and/or CV risk. In over half of these patients, the
prescription of NSAIDs was not in accordance with current guidelines or recommendations made by regulatory
agencies.
Background
Therapeutic intervention in osteoarthritis (OA) is
focused on reducing pain and improving functional
activity [1,2]. Among pharmacological treatments,
NSAIDs are commonly prescribed because of their clini-
cal efficacy, despite the well-known gastrointestinal (GI)
side effects associated with their use [3]. Cyclooxigen-
ase-2 (COX-2)-selective NSAIDs were developed to
diminish the GI adverse events caused by non-selective
NSAIDs (nsNSAIDs) [4]. COX-2-selective and most
nsNSAIDs can be associated with increased cardiovascu-
lar (CV) risk, which has prompted the necessity for
assessments of both GI and CV risk in patients who
need these medications [5-8]. All NSAIDs are also asso-
ciated with other side effects, including hypertension,
water retention, heart failure and renal insufficiency [9].
Based on these findings, the Food and Drug Adminis-
tration (FDA) [10], the European Medicines Agency
(EMA) [11], and different scientific societies [12-14]
agree that the medical management of patients who
r e q u i r eN S A I D sm u s tb eb a s e du p o nt h ep r e v i o u s
assessment of GI and CV risk factors in the individual
patient. Guidelines recommend the use of nsNSAIDs
plus a gastroprotectant or a COX-2-selective NSAID
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[15,16]. A COX-2-selective agent plus a proton pump
inhibitor (PPI) is recommended in those with the high-
est GI risk, whereas nsNSAIDs and COX-2-selective
inhibitors should be avoided in patients with high GI
and CV risks [11-16]. The FDA clearly states that CV
risk is associated with all NSAIDs, excluding aspirin
[10]. The EMA contraindicates the use of the COX-2-
selective agents in patients with previous CV events and
establishes that adverse CV events with the use of
nsNSAIDs cannot be excluded. In addition, the EMA
contraindicates the use of etoricoxib in the presence of
uncontrolled hypertension [11].
It is unknown whether these recommendations made
by regulatory agencies and guidelines are being followed.
Therefore, our study was aimed at evaluating the GI and
CV risk profiles in patients with OA as well as the phar-
macological management and the appropriateness of
therapies based on current recommendations issued by
European guidelines and the European Medicines
Agency [11,12,14,16].
Methods
Sample and design
This was a cross-sectional, multicenter, observational study
in OA patients who were considered candidates for
NSAID medication. All data were collected in one single
day (25 March 2009) in all participating centers. A total of
1,760 investigators from the Spanish National Health Sys-
tem representing the two specialties that most frequently
treat patients with OA in our country’s primary care physi-
cians and orthopedists visited a total of 60,868 consecutive
patients seen in this one day. The investigators registered
the total number of patients who visited their medical cen-
ters on 25 March 2009. Patients included in the study had
to meet the following criteria: 1) male or female aged over
18 years, 2) established diagnosis of osteoarthritis in medi-
cal records, 3) informed verbal consent. Patients received
drug treatment and/or medical care according to the usual
clinical habits of the attending doctor.
Variables related to GI and CV risk classification
The following well known GI risk factors were assessed
[12-17]: age 65 or older; concomitant acetyl salicylic
acid (ASA), corticosteroid, or anticoagulant use; pre-
vious history of ulcers, ulcer bleeding, or dyspepsia; and
the use of two NSAIDs or a high dose of one NSAID (a
dose was considered high if the NSAID was prescribed
at the maximum dose recommended for the sympto-
matic treatment of arthritis pain, as described elsewhere
[17]. CV low dose ASA was considered any dose 300
mg/day or less. Helicobacter pylori infection was not
considered because the proportion of patients from
whom this information was available was very low.
For the purposes of this study and based on previous
reports [12-17], we classified patients into three GI cate-
gories. Patients at low GI risk were considered to be
those without any of the above-mentioned clinical condi-
tions. Patients at moderate GI risk included those with at
least one of the following GI risk factors: 1) age 65 or
older, 2) concomitant use of low-dose ASA, 3) concomi-
tant use of corticosteroids, 4) history of symptomatic
peptic ulcer, 5) history of dyspepsia, 6) current high-dose
NSAID use and, 7) current use of two NSAIDs. As
described elsewhere [17], patients at high GI risk were
those with either a GI bleeding history, concomitant use
of NSAIDs and anticoagulants or the presence of three
risk factors of those described for moderate GI risk or
any of those factors combined with an uncomplicated
peptic ulcer. These combinations were based on the esti-
mated incidence of events obtained from combining dif-
ferent risk factors that would put patients at a similar
risk level to those with a history of bleeding peptic ulcers
[18,19]. In this way, in low GI risk patients, the expected
rate of upper GI complications should not exceed 1.5
events per 100 patients per year, whereas for those at
moderate GI risk, the rate should be between 1.5 to 10,
and for high GI risk patients, the rate should be greater
than 10 events per 100 patients per year. Patients being
treated with anticoagulants (warfarin or coumadin) and
NSAIDs were considered high risk, because bleeding
events in anticoagulated patients can be more severe [20].
In addition to GI risk factors, CV data were also col-
lected which, according to recommendations of different
government agencies and the EMA, limit the use of
some NSAIDs. Information regarding previous CV his-
tory including myocardial infarction, angina, stroke, per-
ipheral arteriopathy or heart failure, was collected.
These diagnoses were confirmed by examination of
patient medical records. Thep r e s e n c eo fh y p e r t e n s i o n
history and anti-hypertensive drug therapy was also col-
lected. Blood pressure levels were obtained at the clini-
cal visit and compared with previous values recorded in
patient charts, if available. Uncontrolled hypertension
was considered if the systolic blood pressure was greater
than 140 mmHg or the diastolic blood pressure greater
than 90 mmHg at the medical visit.
Current OA medications taken by patients and pre-
scriptions made at the clinical visit were also recorded
as well as the type of NSAIDs and gastroprotective
agents used. COX-2-selective agents included celecoxib
or etoricoxib, whereas all other prescribed NSAIDs were
considered non-selective.
Statistical analysis
The descriptive analysis of the patients included demo-
graphic, clinical characteristics, medical history and
pharmacological treatments. Quantitative and qualitative
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tendency (mean, median) and measurements of disper-
sion (95% confidence interval). Furthermore, qualitative
variables were defined according to their absolute and
relative frequencies. The mean and SD are reported for
continuous variables and percentages for qualitative
variables. Student’s t-test was used to analyze continu-
ous variables and the Chi-square test for quantitative
variables. Tests were two-tailed with a significance level
of 5%. Data were analyzed with SAS 8.2 statistical soft-
ware (SAS Institute, Cary, NC, USA). Due to a problem
with the hard copy of the CRF, gender data were not
collected and, therefore, cannot be provided.
Sample size
At least 5,000 patients who met the selection criteria
were estimated for inclusion in the study. This sample
size would allow the estimation of the percentage of
patients with the presence of cardiovascular history
(yes/no) and gastrointestinal risk factors (yes/no), with a
significant level of 95% and a precision 1.5% in a two-
sided test, assuming a population proportion in the
worst case (P = Q = 50%). A replacement rate of 15%
was estimated. A sample size of 17,000 patients covered
this estimate with an accuracy of 0.8%.
Ethical considerations
The study complied with all ethical considerations invol-
ving human subjects, as adopted in the 18
th World
Medical Assembly, Helsinki, Finland. All information
recorded was obtained following standard clinical guide-
lines, and patients were not subjected to any therapeutic
or diagnostic experimentation. The study followed stan-
dard security and confidentiality measures, complying
fully with Spanish legislation regarding data protection
(Ley Orgánica de 15/99). The work was presented to
and approved by the Regional Ethics Committee for
Clinical Research, Hospital Clinic de Barcelona (registra-
tion number 2009/4747). The use of identification num-
bers, instead of other patient identifiers, ensured patient
names remained confidential.
Results
Characteristics of patients
From a total of 60,868 patients seen by the 1,760 partici-
pating investigators in one day, 21,448 patients suffered
from musculoskeletal diseases, but eventually 4,343 were
excluded from the analysis because it was unclear
whether the underlying disease was OA, leaving a final
study sample of 17,105 patients.
Gastrointestinal risk
Figures 1 and 2 summarize the GI risk factors found in
the study population. An age of 65 or older was most
common (76.1%), whereas a history of complicated
ulcers was the least common risk factor (3.3%). Overall,
only 6.6% of patients had no GI risk factors, whereas
the rest had at least one, and 65% had two or more.
Based on these risk factors, >90% of OA patients were
at increased GI risk and 60.3% of them could be consid-
ered at high risk for GI events.
Cardiovascular history
A history of previous CV events and uncontrolled
hypertension are the two CV factors that limit the use
of COX-2-selective agents and nsNSAIDs according to
regulatory agencies. Of 16,470 patients with recorded
CV data, 31.9% (5,256) had a history of at least one pre-
vious CV event; 22.6% (3,647/16,157) had uncontrolled
hypertension and 57.6% (9,540/16,226) were taking anti-
hypertensive drugs. Among those with a history of CV
events, 2,064/5,256 (39.3%) were taking low-dose ASA.
An association between GI and CV risk was observed.
More patients with a positive CV history (Figure 3) or
receiving antihypertensive therapy (71.4% of 9,354
patients) pertained to the high GI risk group than to the
moderate or no GI risk groups.
Pharmacological treatment
The mean number of OA medications prescribed to
patients for underlying OA was 1.9 ± 0.9, and 93.9% of
patients were receiving between one and three treatments.
Of 17,105 patients with information regarding OA ther-
apy, 20.4% were prescribed non-NSAID therapies includ-
ing paracetamol (alone or combined with opioids or
100
76,1
60
70
80
90
00
36,4
21,4 20,3
12,6 12,4
7,9
33 10
20
30
40
50
%
3,3
0
10
Age>65years
(n=13011)
Historyof
dyspepsia
(n=6234)
Concomitant
useofAspirin
(ASA)(n=3652)
Highdoseof
NSAIDs
(n=3466)
Concomitant
useof
anticoagulants
(n= 2159)
Historyof
uncomplicated
pepticulcer
(n= 2116)
Concomitant
useof
corticosteroids
(n=1350)
Historyof
complicated
pepticulcer
(n= 571) (n=2159) (n=2116) (n=1350) (n=571)
Figure 1 GI risk factors in the study population (N = 17,105).
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Page 3 of 7symptomatic slow acting drugs, including glucosamine,
chondroitin sulfate, and diacerein (SYSADOAs) in 18.2%
of cases. NsNSAIDs were prescribed to 46.3% of patients,
and COX-2-selective inhibitors to 32.7%.
Appropriateness of drug use in OA patients based on the
GI and CV risk
Table 1 summarizes drug therapy according to GI risk.
Non-selective NSAIDs were similarly prescribed in the
three GI risk levels, although gastroprotective therapy
and COX-2-selective inhibitors were more frequently
prescribed to those at increased GI risk (P < 0·0001).
Concerning the type of drugs prescribed according to
C Vr i s k ,n s N S A I D sw e r em o r ef r e q u e n t l yp r e s c r i b e dt o
those with no history of CV events (5,452/11,214 =
48.6%) when compared to those with a previous history
of CV events (2,169/5,256 = 41.3%) (P < 0·0001). Over
one-third of patients with and without CV history
received a COX-2-selective NSAID (33.5% vs. 31.7%; P
= 0·02, respectively). Of 3,647 patients with uncontrolled
hypertension, 82% were receiving NSAIDs (nsNSAIDs =
48.4% or COX-2-selective = 33.6%). In 10.7% of these
cases, etoricoxib was the prescribed drug. The prescrip-
tion of naproxen was rather small (3.4% of patients; 586
of 17,105). Of all patients treated with naproxen, 31.1%
(175/562) had a previous CV history, 27.5% (155/563)
had uncontrolled hypertension, and 54.7% (306/559)
were taking antihypertensive treatment.
Within the overall OA population of this study, those
patients with high GI risk and CV history represents
25.3% of the total. As shown in Table 2, 74.4% of this
subpopulation (3,217/4,323 patients) received nsNSAIDs
or COX-2-selective NSAIDs, which is considered inap-
propriate or contraindicated therapy for them, according
to current guidelines [11-16].
Also, patients at high GI risk and no increased CV
risk are recommended to take COX-2-selective NSAIDs
plus PPI [12-16]; within this group, 61.8% of patients
(3,521/5,697) were treated with COX-2-selective
NSAIDs alone or nsNSAIDs plus PPI.
When all figures are combined, (Table 2), 51.03%
(8,406/16,470) of the overall population of OA patients
are being prescribed medications that were either not
recommended or contraindicated, according to current
guidelines and understanding.
Discussion
Current guidelines and recommendations issued by
regulatory agencies [11-16] for patients with GI and
CV risk factors require NSAIDs and have introduced
an unavoidable complexity in the clinical decision-
making process. A recent report has shown that 86%
of OA patients seen by rheumatologists are at
increased GI risk and that almost half of them are at
high CV risk [17]. The current study, carried out at
primary care and orthopedist sites, reached a similar
conclusion.
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Figure 3 Gastrointestinal risk and CV history in the OA study
population.
Table 1 Type of prescription according to GI risk
Type of drug Low GI risk
N (%)
Moderate GI risk
N (%)
High GI risk
N (%)
P-value**
N = 1283 N = 5511 N = 10311
SYSADOA 55 (4.3) 120 (2.2) 80 (0.8) <0.0001
Paracetamol 130 (10.1) 535 (9.7) 841 (8.2) 0.001
Opioids 12 (0.9) 55 (1.0) 59 (0.6) 0.008
Combinations of any of the 3* 80 (6.2) 424 (7.7) 1103 (10.3) <0.0001
NsNSAIDs 615 (47.9) 2,567 (46.6) 4,734 (45.9) 0.337
nsNSAID+ GP*** 344/615 (55.9) 2,093/2,567 (81.5) 4,367/4,734 (92.2) <0.0001
Cox-2 NSAID 294 (22.9) 1,636 (29.7) 3,669 (35.6) <0.0001
Cox-2 + GP*** 96/294 (32.7) 880/1,636 (53.8) 2.800/3,669 (76.3) <0.0001
CV HX = cardiovascular history; GP = gastroprotectant (>91% proton pump inhibitors).
* Sysadoa, paracetamol, opioids; ** P-values denotes differences among groups overall; *** nsNSAIDS + GP data express the number of patients and % of
patients with nsNSAIDs prescription that also take a gastroprotective agent. Also, COX-2 + GP data express the number of patients and % of patients with COX-2
selective inhibitors prescriptions that also take a gastroprotective agent.
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or implemented in clinical practice is generally
unknown. This study has shown that in over half of the
OA population examined, the prescription of NSAIDs
did not follow current guidelines or recommendations.
The most critical areas where the recommendations
were not being followed or were over-looked, were in
patients with both high GI and CV history and in those
with a high GI risk alone. In the first group, over 74% of
cases received prescriptions of either non-selective
NSAIDs or COX-2-selective NSAIDs. In the second
group, 49% received non-selective NSAIDs and a PPI
instead of no NSAID therapy or a COX-2-selective
NSAID and a PPI. Naproxen was seldom prescribed
overall or for those with CV risk, despite being pointed
out as the safest NSAID for those with CV events [21].
However, other recommendations seem to be well
adopted and followed in clinical practice. For example,
our study showed high rates of PPI co-prescription with
nsNSAIDs to patients with increased GI risk. These
rates increased in parallel with higher levels of GI risk.
Similar trends, although with lower rates of prescription,
were observed with COX-2-selective NSAIDs alone.
However, half of patients with low GI risk and no CV
history were still treated with nsNSAIDs plus a PPI or a
COX-2-selective NSAID, which are not recommended
by current guidelines.
Overall, the data suggest that although some of the
recommendations are being followed, others are not;
especially those concerning the assessment of CV risk,
which seems far from being implemented in routine
clinical practice. These data contrast with some other
reports at the specialist level (for example, rheumatolo-
gists), who seem to comply better with existing guide-
lines [17,22].
Increased blood pressure is another frequent side
effect of NSAID therapy. Patients with hypertension
should be monitored when receiving NSAIDs and these
drugs should be avoided when patients suffer from
uncontrolled hypertension. As shown in this study, over
half of the OA study population received antihyperten-
sive therapy and one-fourth had uncontrolled hyperten-
sion. An overwhelming majority of these patients with
uncontrolled hypertension were receiving NSAIDs,
including etoricoxib [11]. This suggests another area for
improvement in clinical practice.
This study had both strengths and limitations. The
strengths include: the cross-sectional approach for the
collection of data in a single day for all patients; and the
size of the study carried out at the primary and orthope-
dist care sites where OA patients are more commonly
treated and prescribed therapy. Other strengths were
the wide geographical distribution within the country
and the fact that the data agreed with recent reports.
This supports the value of the study [17]. Another
important aspect of the study is that it highlights the
existing problem in patients that require NSAID treat-
ment. It reveals the necessity of guideline implementa-
tion strategies to improve clinical practice. Limitations
include the fact that we had to rely on data reported by
the investigators, based on recorded charts, although the
consistency of the data across investigators and the mul-
tiple sites of the study reduced the impact of this limita-
tion. Also, data on uncontrolled hypertension were
based on blood pressure readings obtained during the
clinical visit and confirmed with values previously
recorded in patient charts when available, which may
have overestimated the incidence of hypertension. How-
ever, the CV risk probably was underestimated, because
it was based on the history of CV events; whereas had
Table 2 Type of prescription based on GI risk and CV history
Prescription Low GI risk Mod. GI risk High GI risk P** value
No CV Hx* CV Hx No CV Hx CV Hx No CV Hx CV Hx
N (%) N (%) N (%) N (%) N (%) N (%)
N = 1,144 N = 62 N = 4,373 N = 871 N = 5,697 N = 4,323
SYSADOA 52 (4.6) 0 (0.0) 92 (2.1) 22 (2.5) 44 (0.8) 33 (0.8) <0.0001
Paracetamol 108 (9.4) 13 (21.0) 391 (8.9) 121 (13.9) 331 (5.8) 480 (11.1) <0.0001
Opioids 11 (1.0) 1 (1.6) 40 (0.9) 11 (1.3) 28 (0.5) 28 (0.7) 0.03
Combinations of any of the 3* 72 (6.2) 5 (8.0) 306 (7.0) 97 (11.1) 498 (8.7) 586 (13.5) <0.0001
nsNSAIDs 554 (48.4) 27 (43.5) 2,091 (47.8) 353 (40.5) 2,807 (49.3) 1,789 (41.4) <0.0001
nsNSAID+ GP*** 307/554 (55.4) 18/27 (66.7) 1,687/2,091 (80.7) 302/353 (85.6) 2,552/2,807 (90.9) 1,691/1,789 (94.5) <0.0001
Cox-2 NSAID 267 (23.3) 13 (21.0) 1,335 (30.5) 227 (26.1) 2,154 (37.8) 1,428 (33.0) <0.0001
Cox-2 + GP*** 89/267 (33.3) 4/13 (30.8) 694/1,335 (52.0) 149/227 (65.6) 1,554/2,154 (72.1) 1,177/1,428 (82.4) <0.0001
CV HX = cardiovascular history; GP = gastroprotectant (>91% PPI).
* Sysadoa, paracetamol, opioids; ** P-values denotes differences among groups overall; *** nsNSAIDS + GP data express the number of patients and % of
patients with nsNSAIDs prescription that also take a gastroprotective agent. Also, COX-2 + GP data express the number of patients and % of patients with COX-2
selective inhibitors prescriptions that also take a gastroprotective agent.
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high CV risk might have been higher [17]. However, we
did not use those scores in order to simplify the study
due to the size of the surveyed population. Finally, one
may question whether the data obtained in patients
from one country may apply to other countries.
Whereas this may be true, it is possible that the validity
of the conclusions may apply especially to other Eur-
opean countries due to similarities among health sys-
tems and the similar strategies and guidelines issued by
different European scientific societies under the same
regulatory body (the EMA). However, the high rates of
PPI prescription found in Spain may be different from
those observed in other European countries [23], which
may even increase the gap of appropriate prescriptions
for these patients.
Conclusions
T h i ss t u d yp r o v i d e sv a l u a b l ei n f o r m a t i o no nt h eh i g h
prevalence of both GI and CV risk in OA patients who
receive NSAID therapy. It also reports the high propor-
tion of NSAID prescriptions that are not considered
appropriate according to recommendations given by
professional scientific societies and regulatory agencies.
These data must serve not only to increase awareness of
the limitations and difficulties on the translation of
these recommendations into clinical practice, but also
stimulate the creation of strategies or tools to increase
the appropriate therapy for OA patients at primary care
and orthopedist levels. These strategies may include not
only educational programs but electronic tools [16],
online flags and so on, that may suggest the appropriate
therapy for the individual patient.
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